CeriBell (NASDAQ:CBLL – Get Free Report) shares shot up 4.9% on Monday . The stock traded as high as $24.38 and last traded at $24.38. 81,872 shares changed hands during trading, a decline of 57% from the average session volume of 189,637 shares. The stock had previously closed at $23.24.
Wall Street Analyst Weigh In
Several brokerages have commented on CBLL. Canaccord Genuity Group initiated coverage on shares of CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on CeriBell in a research note on Tuesday, November 5th. They set an “overweight” rating and a $32.00 price target for the company. William Blair initiated coverage on CeriBell in a research note on Tuesday, November 5th. They issued an “outperform” rating on the stock. TD Cowen raised their target price on shares of CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, Bank of America started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell has a consensus rating of “Buy” and a consensus target price of $32.60.
Check Out Our Latest Report on CBLL
CeriBell Price Performance
CeriBell (NASDAQ:CBLL – Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. As a group, equities analysts anticipate that CeriBell will post -2.46 earnings per share for the current year.
Institutional Trading of CeriBell
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC bought a new position in shares of CeriBell during the fourth quarter valued at approximately $128,120,000. TPG GP A LLC purchased a new position in CeriBell during the 4th quarter valued at $102,677,000. Red Tree Management LLC bought a new position in CeriBell in the 4th quarter valued at $57,083,000. Yu Fan purchased a new stake in CeriBell in the fourth quarter worth $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new stake in shares of CeriBell during the fourth quarter worth $28,160,000.
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
- Five stocks we like better than CeriBell
- What Are Dividend Contenders? Investing in Dividend Contenders
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- With Risk Tolerance, One Size Does Not Fit All
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- What is a Death Cross in Stocks?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
